Australian Health Officials Flag Privacy Risks in AI Medical Scribes

Federal concerns mount over AI scribe adoption

Australia's federal health department has identified significant privacy and regulatory concerns surrounding AI medical scribes as their use among doctors has nearly doubled in just over a year, according to government briefing documents obtained by Guardian Australia.

AI scribe tools record and transcribe doctor-patient conversations to generate medical notes automatically. Usage among Australian doctors jumped from 22% in August 2024 to 40% by November 2025, according to polling by the Royal Australian College of General Practitioners. Global usage has reached hundreds of millions of interactions over the past 18 months as physicians seek relief from administrative burdens.

Yet February 2026 Senate estimates briefing documents reveal the department's view that these tools "have little oversight" and raise substantial concerns about their deployment in healthcare settings.

Regulatory gaps and data security questions

The current regulatory framework creates significant gaps. AI scribes are classified as medical devices—and thus subject to Therapeutic Goods Administration oversight—only when they serve a therapeutic purpose. Many tools are marketed as falling outside this regulatory scope.

The health department noted that some suppliers may be unaware their cloud platforms transmit patient data outside Australia, creating data security risks. The department also flagged inconsistent transparency around privacy compliance claims.

Another concern centers on economic incentives. Some suppliers advertise that their tools can increase healthcare provider revenue by 30% without additional patient consultations or hours worked, raising questions about Medicare Benefits Scheme cost implications.

Consent practices vary widely

The department's AI advisory group documented significant variation in how clinicians obtain patient consent for AI scribe use. Officials emphasized that informed consent requires patients to understand both benefits and limitations of the technology.

Dr. Elizabeth Deveny, chief executive of the Consumer Health Forum, told Guardian Australia the forum is increasingly hearing from patients who were told to find different providers if they refused consent for AI scribes. Guardian Australia previously reported on a Melbourne psychiatrist who declined to accept patients unwilling to consent to AI scribe use.

Why it matters

The rapid adoption of AI scribes without clear regulatory oversight creates a test case for how healthcare systems manage emerging AI technologies. While these tools promise to reduce physician burnout and administrative load, the lack of consistent safeguards around patient consent, data security, and clinical accountability could undermine trust in digital health infrastructure. The tension between efficiency gains and patient rights will likely shape broader AI governance frameworks in healthcare.

Regulatory review underway

Oversight of AI scribes currently falls to multiple regulators including the Therapeutic Goods Administration, Australian Health Practitioner Regulation Agency, and the Office of the Australian Information Commissioner.

The TGA is conducting a review of digital scribes to determine whether they should be classified as medical devices subject to regulatory oversight, with results expected in coming months. Privacy Commissioner Carly Kind said in May that her office has been tracking the technology's rollout closely and engaging with concerned civil society organizations about deficiencies in consent protocols.

Deveny questioned whether time savings from AI scribes translate to better patient care or simply more billable activity. "The public deserves to know if that time means better care, better access, or if it just means more billable activity, which doesn't help us with the burnout issue," she said.

These details were first reported by Guardian Australia.